Cargando…

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates

OBJECTIVES: To investigate the increase in the rates of OXA-48-like-producing isolates during 3 years of global surveillance. METHODS: Among 55?>162 Enterobacterales isolates, 354 carbapenem-resistant isolates carried genes encoding OXA-48-like enzymes. Isolates were susceptibility tested for cef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castanheira, Mariana, Doyle, Timothy B, Collingsworth, Timothy D, Sader, Helio S, Mendes, Rodrigo E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598286/ https://www.ncbi.nlm.nih.gov/pubmed/34459890 http://dx.doi.org/10.1093/jac/dkab306

Ejemplares similares

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

1238. Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States
por: Castanheira, Mariana, et al.
Publicado: (2021)

1443. Activity of Ceftazidime-Avibactam against Carbapemenase-negative Carbapenem-resistant Enterobacterales (CRE) Isolates from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2020)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)

1284. Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam
por: Castanheira, Mariana, et al.
Publicado: (2021)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
por: Marino, Andrea, et al.
Publicado: (2023)

26. in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism
por: Castanheira, Mariana, et al.
Publicado: (2020)

2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
por: Castanheira, Mariana, et al.
Publicado: (2023)

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
por: Castanheira, Mariana, et al.
Publicado: (2022)

1218. Activity of Meropenem-Vaborbactam and Comparator Agents Against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021)

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023)

200. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against AmpC Hyperproducing Enterobacterales and P. aeruginosa Collected from United States (US) Medical Centers (2016-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole-Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents
por: Castanheira, Mariana, et al.
Publicado: (2017)

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents
por: Sader, Helio S, et al.
Publicado: (2021)

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients
por: Sader, Helio S, et al.
Publicado: (2021)

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era
por: Bianco, Gabriele, et al.
Publicado: (2022)

1296. Efficacy of Human-Simulated Exposures of Meropenem/Vaborbactam (MVB) and Meropenem (MEM) against OXA-48 β-lactamase-producing Enterobacterales in the Neutropenic Murine Thigh Infection Model
por: Gill, Christian M, et al.
Publicado: (2020)

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy
por: Alqahtani, Hajar, et al.
Publicado: (2022)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2020)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
por: Gaibani, Paolo, et al.
Publicado: (2022)

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy
por: Arcari, Gabriele, et al.
Publicado: (2023)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023)

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
por: Fröhlich, Christopher, et al.
Publicado: (2019)

1949. Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US; 2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
por: Carvalhaes, Cecilia G., et al.
Publicado: (2020)

2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021
por: Zilberberg, Marya D, et al.
Publicado: (2023)

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)
por: Sader, Helio S, et al.
Publicado: (2023)

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
por: Shortridge, Dee, et al.
Publicado: (2022)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)
por: Sader, Helio S., et al.
Publicado: (2023)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
por: Oliva, Alessandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4j318u1d3cv0ucr0hostb8mh99